A phase 2 study reveals promising efficacy and safety of TKI and inotuzumab ozogamicin therapy for newly diagnosed Ph+ ALL, achieving high response rates.
Anand A. Patel, MD
Anand A. Patel, MD, is an assistant professor of medicine at the University of Chicago.
Articles by Anand A. Patel, MD